Bridgeway Capital Management LLC Takes Position in VYNE Therapeutics Inc. (NASDAQ:VYNE)

Bridgeway Capital Management LLC acquired a new stake in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 36,958 shares of the company’s stock, valued at approximately $124,000.

A number of other hedge funds also recently made changes to their positions in the company. Schonfeld Strategic Advisors LLC raised its stake in shares of VYNE Therapeutics by 4.8% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 176,658 shares of the company’s stock valued at $592,000 after purchasing an additional 8,058 shares during the period. Jane Street Group LLC bought a new stake in shares of VYNE Therapeutics in the fourth quarter worth $68,000. XTX Topco Ltd bought a new stake in shares of VYNE Therapeutics in the fourth quarter worth $70,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of VYNE Therapeutics in the fourth quarter worth $516,000. Finally, Acorn Capital Advisors LLC bought a new stake in shares of VYNE Therapeutics in the fourth quarter worth $1,531,000. Hedge funds and other institutional investors own 83.78% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright dropped their price target on shares of VYNE Therapeutics from $5.75 to $4.50 and set a “buy” rating for the company in a research note on Friday, April 25th.

VYNE Therapeutics Trading Up 4.8%

Shares of NASDAQ:VYNE opened at $1.31 on Wednesday. The company has a fifty day simple moving average of $1.64 and a 200 day simple moving average of $2.39. The firm has a market cap of $19.93 million, a PE ratio of -1.52 and a beta of 1.76. VYNE Therapeutics Inc. has a 12-month low of $1.18 and a 12-month high of $4.30.

VYNE Therapeutics (NASDAQ:VYNE) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.09. The business had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.05 million. VYNE Therapeutics had a negative net margin of 6,896.55% and a negative return on equity of 43.73%. As a group, equities research analysts forecast that VYNE Therapeutics Inc. will post -0.97 EPS for the current fiscal year.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.